Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN)

31.05
Delayed Data
As of 1:05pm ET
 +0.20 / +0.65%
Today’s Change
13.92
Today|||52-Week Range
31.35
+22.97%
Year-to-Date
Market Goes on a 'Buy the Dip' Trip
Mar 27 / TheStreet.com - Paid Partner Content
Shark Bites: Even Without Health Care Vote, Market's Feeling Better
Mar 24 / TheStreet.com - Paid Partner Content
There's No Rush for the Exits So Far
Mar 27 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close30.85
Today’s open30.85
Day’s range30.71 - 31.30
Volume172,841
Average volume (3 months)546,705
Market cap$1.5B
Dividend yield--
Data as of 1:05pm ET, 03/29/2017

Growth & Valuation

Earnings growth (last year)+528.57%
Earnings growth (this year)--
Earnings growth (next 5 years)+50.00%
Revenue growth (last year)+48.87%
P/E ratio17.6
Price/Sales6.07
Price/Book8.04

Competitors

 Today’s
change
Today’s
% change
AERIAerie Pharmaceutical...0.000.00%
ARRYArray Biopharma Inc-0.12-1.29%
LXRXLexicon Pharmaceutic...+0.53+3.74%
SRPTSarepta Therapeutics...-0.10-0.34%
Data as of 1:22pm ET, 03/29/2017

Financials

Next reporting dateMay 15, 2017
EPS forecast (this quarter)$0.24
Annual revenue (last year)$215.0M
Annual profit (last year)$91.2M
Net profit margin42.43%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, CEO, Secretary &
Director
Jack A. Khattar
CFO, Vice President &
Head-Investor Relations
Gregory S. Patrick
Corporate headquarters
Rockville, Maryland

Forecasts


Search for Jobs